



Gastric Cancer Metastases

Guest Editor:

Dr. Yu-Yin Liu

Division of General Surgery,
Department of Surgery,
Kaohsiung Chang Gung Memorial
Hospital and Chang Gung
University College of Medicine,
No.123, Dapi Rd., Niasong Dist.,
Kaohsiung City, Taiwan

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editor

Gastric cancer is becoming increasingly common. The high mortality rate of these tumors is due to the high percentage of distant metastasis, while cancer was only recently diagnosed. Distant metastases, relating to liver, para-aortic lymph nodes, peritoneal seeding, etc., have been poor prognostic factors in the past. However, more and more new chemotherapeutic agents and forms of immunotherapy have been announced, and conversion surgery has provided the chance of finding a cure for stage IV gastric cancer. Even the patients which could not get an R0 resection still had a better survival rate than supportive treatment or chemotherapy alone. In this Special Issue, experts in this field will review the current approaches to the management of gastric patients with distant metastasis. We would like to focus on conversion surgery and immunotherapy for stage IV patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)